Brokerages Set Intellia Therapeutics, Inc. (NASDAQ:NTLA) Price Target at $48.71
Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the eighteen ratings firms that are presently covering the company, MarketBeat.com reports. Six analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to […]
Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the eighteen ratings firms that are presently covering the company, MarketBeat.com reports. Six analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to […]
